CD274 and cancer: Furthermore, as PD-1 signaling inhibits glycolysis in T cells and PD-L1 in cancer cells stimulates aerobic glycolysis, this reciprocal glucose uptake associated with the PD-1-PD-L1 axis can be applied to metabolic modulation with immune checkpoint inhibitors (ICIs) as a new strategy for cancer immunotherapy (14, 15).